Adjuvant therapy in rectal cancer: a protocol proposal.

Abstract:

:The use of adjuvant radiation therapy and chemotherapy diminishes the likelihood of local-regional and distant recurrences and appears to prolong survival in patients who have undergone a complete surgical resection of a Dukes-Kirklin stage B2 or C rectal cancer. Patients with this malignant condition rarely develop peritoneal recurrences and therefore do not seem to be an appropriate group in which to evaluate the efficacy of intraperitoneal chemotherapy in gastrointestinal cancer. Such individuals, however, might serve as ideal subjects to examine objectively the merits of prolonged, ambulatory infusional chemotherapy through a prospective clinical trial comparing postoperative radiation therapy combined with 5-FU given in either protracted continuous infusional or intermittent bolus schedules.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Mayer RJ

subject

Has Abstract

pub_date

1985-09-01 00:00:00

pages

116-20

issue

3 Suppl 4

eissn

0093-7754

issn

1532-8708

pii

0093-7754(85)90086-7

journal_volume

12

pub_type

杂志文章
  • The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma.

    abstract::Many patients with Hodgkin's and non-Hodgkin's lymphoma (NHL) can be cured today with combination chemotherapy and/or radiotherapy. However, for patients with suboptimal responses to initial therapy or for patients with refractory or relapsed disease, salvage therapy alone is usually inadequate to achieve long-term su...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Laport GF,Williams SF

    更新日期:1998-08-01 00:00:00

  • Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma.

    abstract::Malignant biliary obstruction, duodenal, and gastric outlet obstruction, and tumor-related pain are the complications of unresectable pancreatic adenocarcinoma that most frequently require palliative intervention. Surgery involving biliary bypass with or without gastrojejunostomy was once the mainstay of treatment in ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.12.014

    authors: Stark A,Hines OJ

    更新日期:2015-02-01 00:00:00

  • Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.

    abstract::The current study was conducted to determine the risk of adverse outcomes among patients with monoclonal gammopathy of undetermined significance (MGUS) of the IgM class. Two hundred thirteen patients with IgM MGUS were identified in southeastern Minnesota from 1960 to 1994. The primary end point was progression to lym...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/sonc.2003.50062

    authors: Kyle RA,Therneau TM,Rajkumar SV,Offord JR,Larson DR,Plevak MF,Melton LJ 3rd

    更新日期:2003-04-01 00:00:00

  • The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.

    abstract::Letrozole has proven efficacious in a variety of therapeutic scenarios, including that of extended adjuvant therapy following 5 years of tamoxifen treatment in postmenopausal women with estrogen-receptor-positive early breast cancer. The Breast International Group 1-98 trial (BIG 1-98) is the first to study the effica...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1053/j.seminoncol.2006.03.026

    authors: Forbes JF

    更新日期:2006-04-01 00:00:00

  • Small cell carcinoma of the lung: cellular origin and relationship to other neoplasms.

    abstract::Many small cell carcinomas share morphological and physiological characteristics with normal and neoplastic cells of Pearse's APUD series, including pulmonary APUD cells and pulmonary carcinoid tumors. There is very likely more than one type of APUD cell in the lung, and conclusions that small cell carcinomas and carc...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Tischler AS

    更新日期:1978-09-01 00:00:00

  • Clinical pharmacokinetics of fluorouracil and folinic acid.

    abstract::This article deals with the pharmacokinetics of fluorouracil (5-FU) and folinic acid (CHO-THF). 5-FU kinetics are characterized by short serum half-life times of 4.5 to 13 minutes. The high body clearance is mainly caused by a rapid catabolism of 5-FU to dihydrofluorouracil (FUH2), alpha-fluoro-ureidopropionic acid (F...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Schalhorn A,Kühl M

    更新日期:1992-04-01 00:00:00

  • Central nervous system disease in hematologic malignancies: historical perspective and practical applications.

    abstract::Acute lymphoblastic leukemia (ALL) 5-year survival rates are approaching 90% in children and 50% in adults who are receiving contemporary risk-directed treatment protocols. Current efforts focus not only on further improving cure rate but also on patient quality of life. Hence, all protocols decrease or limit the use ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2009.05.002

    authors: Pui CH,Thiel E

    更新日期:2009-08-01 00:00:00

  • Total necrosis of hepatocellular carcinoma with a combination therapy of arterial infusion of chemotherapeutic lipiodol and transcatheter arterial embolization: report of 14 cases.

    abstract::Combination therapy consisting of Lipiodol (Laboratoire Guerbet, Villepinte, France) containing styrene maleic acid neocarzinostatin and transcatheter arterial embolization (L-TAE) has been an important conservative therapy for hepatocellular carcinoma (HCC). We examined the clinical and pathologic characteristics of ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Kenji J,Hyodo I,Tanimizu M,Tanada M,Nishikawa Y,Hosokawa Y,Mandai K,Moriwaki S

    更新日期:1997-04-01 00:00:00

  • Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia.

    abstract::Preclinical models in vitro and in vivo have shown that tumor hypoxia alters the malignant cell phenotype, selecting for p53 mutations, stimulating angiogenesis and metastasis, and markedly reducing the efficacy of both radiotherapy and chemotherapy. Similarly, clinical studies measuring pretreatment tumor oxygen stat...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.31531

    authors: Gandara DR,Lara PN Jr,Goldberg Z,Le QT,Mack PC,Lau DH,Gumerlock PH

    更新日期:2002-02-01 00:00:00

  • Management of early and locally advanced cervical cancer.

    abstract::Cervical cancer is the second most common malignancy in women and the third most common cause of cancer mortality worldwide. While primary and secondary preventions exist, the lack of widespread adoption leaves the treatment of cervical cancer an important oncologic problem. In this article, the management of early an...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2008.12.007

    authors: Barbera L,Thomas G

    更新日期:2009-04-01 00:00:00

  • The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.

    abstract::In recent years, several new cytotoxic agents have been investigated for the management of non-small cell lung cancer (NSCLC), including the antimetabolic gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) and the new multitargeted antifolate pemetrexed (Alimta, Eli Lilly and Company), which are both among ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00284-7

    authors: Le Chevalier T

    更新日期:2003-08-01 00:00:00

  • Chronic oral etoposide: trials at Indiana University and with the Hoosier Oncology Group.

    abstract::Etoposide has proven to be an active agent in the treatment of a variety of neoplasms, particularly germ cell cancers and small cell lung cancer. Yet despite its widespread use, the optimal dose and schedule for etoposide remain unknown. The fact that its efficacy appears to be schedule dependent, along with the recen...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Loehrer PJ Sr

    更新日期:1992-12-01 00:00:00

  • Pain management issues as part of the comprehensive care of the cancer patient.

    abstract::Pain is a common, feared, but treatable component of malignancy. The ability, however, to successfully relieve the difficult symptoms of progressive disease, including pain, require an understanding of tumor behavior, complications, and cancer therapy. Despite the treatability of cancer pain and multiple clinical opti...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Brescia FJ

    更新日期:1993-04-01 00:00:00

  • Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine.

    abstract::Organ function preservation in patients with head and neck cancer can be achieved by intensity-modulated radiation therapy (IMRT). Much of the work on the physics of IMRT has been done for currently available IMRT systems. However, clinical data remain scarce. Before IMRT is accepted as a standard of care, more compre...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,评审

    doi:10.1053/j.seminoncol.2003.11.009

    authors: Chao KS,Ozyigit G,Thorsdad WL

    更新日期:2003-12-01 00:00:00

  • A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.

    abstract::This phase I study was designed to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) with standard doses of cisplatin and etoposide for patients with untreated, extensive-stage small cell lung cancer. Secondary objectives were to determine the toxicities, response ...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Bunn PA Jr,Kelly K

    更新日期:1997-08-01 00:00:00

  • Antifolates in clinical development.

    abstract::Many novel antifolate compounds with unique pharmacologic properties are currently in clinical development. These newer antifolates differ from methotrexate, the most widely used and studied drug in this class, in terms of their lipid solubility and cellular transport affinity, their level of polyglutamation, and thei...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Takimoto CH

    更新日期:1997-10-01 00:00:00

  • African American men, prostate cancer early detection examination use, and informed decision-making.

    abstract::It is well known that African American men are more likely to be diagnosed with metastatic prostate cancer than White men. Racial variation in the use of prostate cancer early detection modalities (ie, digital rectal examination [DRE] and prostate-specific antigen [PSA] testing) has been suggested as a major reason fo...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Myers RE

    更新日期:1999-08-01 00:00:00

  • New targeted therapies in breast cancer.

    abstract::Targeted therapy for breast cancer has existed since 1986, when Beatson published his observations on oophorectomy. In the past 5 years monoclonal antibodies and tyrosine kinase inhibitors have been evaluated in phase I and II clinical trials of breast cancer. Trastuzumab (Herceptin; Genentech, Inc, South San Francisc...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.02.018

    authors: Kaklamani V,O'Regan RM

    更新日期:2004-04-01 00:00:00

  • Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials.

    abstract::The potential benefits of docetaxel (Taxotere; Aventis, Antony, France) to patients with previously-treated non-small cell lung cancer have been evaluated in two prospective randomized phase III trials. In one study, patients with stage IIIB/IV non-small cell lung cancer who had failed previous cisplatin-based chemoth...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Shepherd FA,Fossella FV,Lynch T,Armand JP,Rigas JR,Kris MG

    更新日期:2001-02-01 00:00:00

  • Liver transplantation in Langerhans' cell histiocytosis (histiocytosis X).

    abstract::Two children with biopsy-proven LCH underwent successful hepatic transplantation for end-stage liver disease. These patients were thought not to have active LCH disease at the time of transplantation, although one had developed a new osteolytic lesion a few months before the operation and the other had suspicious oste...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Concepcion W,Esquivel CO,Terry A,Nakazato P,Garcia-Kennedy R,Houssin D,Cox KL

    更新日期:1991-02-01 00:00:00

  • The expanding role of cisplatin in the treatment of non-small-cell lung cancer.

    abstract::Cisplatin has been employed in the treatment of non-small-cell lung cancer (NSCLC) since the late 1970s. Current evidence suggests that it may be the most effective single drug for the treatment of NSCLC patients. The overall response rate as a single agent is 21%, though responses are higher in previously untreated p...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Bunn PA Jr

    更新日期:1989-08-01 00:00:00

  • Nimotuzumab: beyond the EGFR signaling cascade inhibition.

    abstract::One of the most known oncogenes is the epidermal growth factor receptor (EGFR) family. It activates multiple signaling cascades that promote carcinogenesis and immune evasion. Therefore, these molecules have been extensively targeted in cancer immunotherapy. Beyond EGFR signaling cascade inhibition, some of these agen...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2018.04.008

    authors: Mazorra Z,Chao L,Lavastida A,Sanchez B,Ramos M,Iznaga N,Crombet T

    更新日期:2018-01-01 00:00:00

  • The use of ondansetron in patients receiving multiple-day cisplatin regimens.

    abstract::The control of nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy has remained difficult, even with the use of combination antiemetic regimens containing metoclopramide. Although these patients receive a lower daily dose of cisplatin, the emetogenic potential remains high. In addition, many ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hainsworth JD

    更新日期:1992-08-01 00:00:00

  • Mechanism of action of trastuzumab and scientific update.

    abstract::The humanized anti-p185(HER2) monoclonal antibody trastuzumab has been shown to effectively inhibit the growth of HER2-overexpressing breast cancer cells in vivo and in vitro. The treatment of cancer cells with trastuzumab results in downregulation of the HER2 receptor. Further downstream cellular events include the a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90276-3

    authors: Baselga J,Albanell J,Molina MA,Arribas J

    更新日期:2001-10-01 00:00:00

  • The current status of toxicity protectants in cancer therapy.

    abstract::Current therapies for the treatment of malignancies are associated with significant toxicity, as chemotherapy and radiation therapy do not discriminate between normal and malignant cells. One approach to ameliorating the toxicity associated with therapy is through the use of chemoprotective agents. This article review...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Schuchter LM,Luginbuhl WE,Meropol NJ

    更新日期:1992-12-01 00:00:00

  • In vitro data supporting interferon plus cytotoxic agent combinations.

    abstract::The human tumor cloning system is an in vitro assay that has been used to predict response of patients' tumors to conventional antineoplastic agents as well as to biologic agents. In addition, the assay has been used to screen for antitumor activity of newly discovered cytotoxics and biologics. The purpose of the pres...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Von Hoff DD

    更新日期:1991-10-01 00:00:00

  • Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.

    abstract::Thrombocytopenia is a significant problem for patients receiving prolonged or aggressive chemotherapy for malignancy. For carboplatin, it is the predominant dose-limiting toxicity and it is cumulative in nature. A number of agents have been evaluated for efficacy in reducing the problem of thrombocytopenia. Some have ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Budd GT,Ganapathi R,Wood L,Snyder J,McLain D,Bukowski RM

    更新日期:1999-04-01 00:00:00

  • Future directions in the chemotherapy of ovarian cancer.

    abstract::Clinical research in the treatment of epithelial ovarian cancer has entered a new phase. A pivotal Gynecologic Oncology Group study demonstrated that paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus cisplatin was superior to the previous standard therapy of cyclophosphamide plus cisplatin. Confirma...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Ozols RF

    更新日期:1997-10-01 00:00:00

  • Pox viral vaccine approaches.

    abstract::Recent advances in understanding tumor-specific immunity have introduced new excitement in the clinical development of vaccines for the treatment of cancer. A better understanding of basic immunologic principles has led to a variety of techniques for enhancing tumor-specific immunity through vaccination. Approaches to...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.09.006

    authors: Arlen PM,Kaufman HL,DiPaola RS

    更新日期:2005-12-01 00:00:00

  • Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team.

    abstract::In this feasibility study, a 3-hour infusion of 225 mg/m2 paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was combined with carboplatin dosed to an area under the concentration-time curve of 6 to treat patients with stage T2N0, T1-2N1, or T3N0-1 (excluding superior sulcus tumors) non-small cell lung ca...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Pisters KM,Kris MG,Bunn PA Jr,Johnson DH,Ruckdeschel JC,Crowley JJ,Ginsberg RJ

    更新日期:1997-08-01 00:00:00